PicoCELA Inc. (NASDAQ:PCLA) Short Interest Update

PicoCELA Inc. (NASDAQ:PCLA) was the target of a large decrease in short interest in the month of June. As of June 15th, there was short interest totaling 37,187 shares, a decrease of 70.6% from the May 31st total of 126,693 shares. Approximately 93.0% of the shares of the company are sold short. Based on an average trading volume of 116,946 shares, the short-interest ratio is presently 0.3 days.

Institutional Investors Weigh In On PicoCELA

A hedge fund recently bought a new position in PicoCELA stock. Jane Street Group LLC bought a new stake in shares of PicoCELA Inc. (NASDAQ:PCLA) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 172,132 shares of the company’s stock, valued at approximately $52,000. Jane Street Group LLC owned approximately 18.92% of PicoCELA at the end of the most recent quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of PicoCELA in a research note on Wednesday, April 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Key Headlines Impacting PicoCELA

Here are the key news stories impacting PicoCELA this week:

• Positive Sentiment: PCLA experienced multiple LULD pauses throughout the day, indicating extreme price swings and very active trading interest. Repeated halts often accompany a sharp momentum move and can attract additional speculative volume. LULD pause trading halts
• Neutral Sentiment: Recent short-interest updates were mixed: one report showed short interest falling sharply in mid-June, while another later filing listed zero shares short. That data is unusual and may reflect limited float or reporting anomalies rather than a clear fundamental catalyst. Short interest updates

PicoCELA Stock Performance

Shares of NASDAQ PCLA traded up $3.90 during mid-day trading on Friday, reaching $6.97. The company’s stock had a trading volume of 7,267,545 shares, compared to its average volume of 92,911. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.57 and a current ratio of 2.13. PicoCELA has a 52 week low of $1.35 and a 52 week high of $112.20. The stock has a fifty day moving average of $4.26 and a two-hundred day moving average of $4.81.

About PicoCELA

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.